Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer

Inclusion Criteria

• •Patients must have histologically confirmed advanced, prostate cancer
• •Patients must have evaluable disease that may be evaluated by PSA or measurement.
• •Patients must be hormone refractory as defined in this protocol.
• •Patients must be taxane refractory as defined in this protocol.
• •Patients have had no prior chemotherapy other than a taxane or estramustine phosphate.
• •Patients may have had prior radiation therapy (RT) if it has been \>/= 4 weeks since completion.
• •Patients on bisphosphonates may be included.
• •Patients must be at least 18 years of age or older.
• •Patients must have the ability to speak and understand English.
• •Patients must have an ECOG performance status of 2 or less.
• •Patients must have adequate bone marrow function: platelets \> 100,000 cells/mm3; hemoglobin \> 9.0 g/dL; and absolute neutrophil count (ANC) \> 1,000 cells/mm3.
• •Patients must have adequate renal function: creatinine \< 2.5 mg/dL.
• •Patients must have adequate liver function.
• •Ejection fraction of \> 50% within 42 days of first dose of study drug.
• •Ability to complete the McGill-Melzack Pain Intensity Scale.